Literature DB >> 2050179

Doxycycline tolerance study. Incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs Vibramycin').

M J Story1, P I McCloud, G Boehm.   

Abstract

In a randomised, double-blind, 3-way cross-over trial, the incidence of nausea associated with 2 doxycycline 100 mg formulations (Doryx' and Vibramycin') were compared. The original study cohort comprised 103 healthy male volunteers, with 97 subjects completing the trial. Subjects were randomly allocated to 1 of 3 treatment sequences and received a single dose of Doryx', Vibramycin' or placebo, with a 7-day washout prior to cross-over. At half-hourly intervals, from 0 to 2 h post-dose, subjects completed questionnaires to indicate if they felt nauseous. Data were analysed according to a log-linear method for the analysis of cross-over trials with categorical responses. Seventeen, 29 and 11 subjects experienced nausea with Doryx', Vibramycin' and placebo, respectively. A significantly greater number of volunteers indicated a positive response with Vibramycin' vs Doryx' and vs placebo; the positive response frequency was not significantly different for the Doryx' vs the placebo regimen. Treatment sequence had no significant effect on response, although a marked first-dose effect was noted; the first (vs the second and vs the third) regimen was 1.5-2 times more likely to induce a positive response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050179     DOI: 10.1007/bf00265856

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  Absorption of doxycycline from a controlled release pellet formulation: the influence of food on bioavailability.

Authors:  D B Williams; W J O'Reilly; G Boehm; M J Story
Journal:  Biopharm Drug Dispos       Date:  1990-03       Impact factor: 1.627

2.  A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R.

Authors:  R S Berger
Journal:  J Clin Pharmacol       Date:  1988-04       Impact factor: 3.126

3.  Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects.

Authors:  P G Welling; P A Koch; C C Lau; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

  3 in total
  4 in total

Review 1.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2013-12-11

Review 2.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2008-03-10

3.  Enteric Coating Reduces Upper Gastrointestinal Adverse Reactions to Doxycycline.

Authors:  A Järvinen; S Nykänen; L Paasiniemi; T Hirsjärvi-Lahti; J Mattila
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

4.  Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses.

Authors:  Heidi Zozaya; Lilia Gutierrez; Maria Josefa Bernad; Hector Sumano
Journal:  Acta Vet Scand       Date:  2013-03-08       Impact factor: 1.695

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.